Sökning: WFRF:(Comans Emile F I) > Blood-brain barrier...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03949naa a2200493 4500 | |
001 | oai:DiVA.org:uu-169981 | |
003 | SwePub | |
008 | 120307s2012 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1699812 URI |
024 | 7 | a https://doi.org/10.1093/brain/awr2982 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a van Assema, Danielle M. E.4 aut |
245 | 1 0 | a Blood-brain barrier P-glycoprotein function in Alzheimer's disease |
264 | c 2011-11-25 | |
264 | 1 | b Oxford University Press (OUP),c 2012 |
338 | a print2 rdacarrier | |
520 | a A major pathological hallmark of Alzheimer's disease is accumulation of amyloid-beta in senile plaques in the brain. Evidence is accumulating that decreased clearance of amyloid-beta from the brain may lead to these elevated amyloid-beta levels. One of the clearance pathways of amyloid-beta is transport across the blood-brain barrier via efflux transporters. P-glycoprotein, an efflux pump highly expressed at the endothelial cells of the blood-brain barrier, has been shown to transport amyloid-beta. P-glycoprotein function can be assessed in vivo using (R)-[C-11]verapamil and positron emission tomography. The aim of this study was to assess blood-brain barrier P-glycoprotein function in patients with Alzheimer's disease compared with age-matched healthy controls using (R)-[C-11]verapamil and positron emission tomography. In 13 patients with Alzheimer's disease (age 65 +/- 7 years, Mini-Mental State Examination 23 +/- 3), global (R)-[C-11]verapamil binding potential values were increased significantly (P = 0.001) compared with 14 healthy controls (aged 62 +/- 4 years, Mini-Mental State Examination 30 +/- 1). Global (R)-[C-11]verapamil binding potential values were 2.18 +/- 0.25 for patients with Alzheimer's disease and 1.77 +/- 0.41 for healthy controls. In patients with Alzheimer's disease, higher (R)-[C-11]verapamil binding potential values were found for frontal, parietal, temporal and occipital cortices, and posterior and anterior cingulate. No significant differences between groups were found for medial temporal lobe and cerebellum. These data show altered kinetics of (R)-[C-11]verapamil in Alzheimer's disease, similar to alterations seen in studies where P-glycoprotein is blocked by a pharmacological agent. As such, these data indicate that P-glycoprotein function is decreased in patients with Alzheimer's disease. This is the first direct evidence that the P-glycoprotein transporter at the blood-brain barrier is compromised in sporadic Alzheimer's disease and suggests that decreased P-glycoprotein function may be involved in the pathogenesis of Alzheimer's disease. | |
653 | a P-glycoprotein | |
653 | a blood-brain barrier | |
653 | a PET | |
653 | a Alzheimer's disease | |
653 | a (R)-[C-11]verapamil | |
700 | 1 | a Lubberink, Marku Uppsala universitet,Enheten för nuklearmedicin och PET4 aut0 (Swepub:uu)marklubb |
700 | 1 | a Bauer, Martin4 aut |
700 | 1 | a van der Flier, Wiesje M.4 aut |
700 | 1 | a Schuit, Robert C.4 aut |
700 | 1 | a Windhorst, Albert D.4 aut |
700 | 1 | a Comans, Emile F. I.4 aut |
700 | 1 | a Hoetjes, Nikie J.4 aut |
700 | 1 | a Tolboom, Nelleke4 aut |
700 | 1 | a Langer, Oliver4 aut |
700 | 1 | a Mueller, Markus4 aut |
700 | 1 | a Scheltens, Philip4 aut |
700 | 1 | a Lammertsma, Adriaan A.4 aut |
700 | 1 | a van Berckel, Bart N. M.4 aut |
710 | 2 | a Uppsala universitetb Enheten för nuklearmedicin och PET4 org |
773 | 0 | t Braind : Oxford University Press (OUP)g 135, s. 181-189q 135<181-189x 0006-8950x 1460-2156 |
856 | 4 | u https://academic.oup.com/brain/article-pdf/135/1/181/17863150/awr298.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-169981 |
856 | 4 8 | u https://doi.org/10.1093/brain/awr298 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy